
# CD34 Antibody for FACS / Leukemia Stem Cell Marker Antibody [clone ICO-115] (V2065)

| Catalog No. | Formulation | Size |
|---|---|---|
| V2065-100UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide | 100 ug |
| V2065-20UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide | 20 ug |
| V2065SAF-100UG | 1 mg/ml in 1X PBS; BSA free, sodium azide free | 100 ug |


Citations (5)

**Bulk quote request**

| | |
|---|---|
| **Species Reactivity** | Human, Rat |
| **Format** | Purified |
| **Host** | Mouse |
| **Clonality** | Monoclonal (mouse origin) |
| **Isotype** | Mouse IgG1, kappa |
| **Clone Name** | ICO-115 |
| **Purity** | Protein G affinity chromatography |
| **Buffer** | 1X PBS, pH 7.4 |
| **Gene ID** | 947 |
| **Localization** | Cell surface |
| **Applications** | ELISA (order BSA/sodium azide-free format for coating)<br>Flow cytometry: 1-2ug/million cells<br>Immunofluorescence: 0.5-1ug/ml |
| **Limitations** | This CD34 Antibody for FACS / Leukemia Stem Cell Marker Antibody is available for research use only. |




CD34 Antibody for FACS. Flow cytometry analysis of CD34 surface expression in human KG-1 cells using a Leukemia Stem Cell Marker Antibody, clone ICO-115, shows a clear right-shifted population (red) compared to isotype control (green), indicating specific detection of CD34-positive cells. The distinct population separation supports accurate gating of leukemia-associated blast populations and highlights the antibodyâ€™s utility for flow cytometry analysis of hematologic malignancies.




SDS-PAGE Analysis of Purified, BSA-Free CD34 Antibody for FACS / Leukemia Stem Cell Marker Antibody (clone ICO-115). Confirmation of Integrity and Purity of the Antibody.

## Description

Cluster of Differentiation 34 (CD34) is a transmembrane cell surface glycoprotein encoded by the CD34 gene and expressed on hematopoietic stem and progenitor cells, as well as certain endothelial populations. It is involved in cell adhesion and migration and serves as a key marker of early hematopoietic differentiation. CD34 Antibody for FACS is particularly important in the analysis of hematologic malignancies, where it enables identification and quantification of CD34-positive blast populations using flow cytometry.

CD34 antibody, also known as leukemia stem cell marker antibody or blast cell detection antibody, is widely used in flow cytometry to distinguish immature malignant cells from more differentiated hematopoietic populations. In diseases such as acute myeloid leukemia (AML), CD34 expression is commonly associated with early-stage blast cells, allowing clear identification of malignant progenitor populations within heterogeneous samples. This distinct expression pattern supports accurate gating and separation of CD34-positive blasts during FACS analysis.

This CD34 Antibody for FACS is uniquely positioned for leukemia and cancer stem cell analysis, where precise detection of CD34-positive populations is critical for understanding disease biology and cellular hierarchy. Flow cytometry enables quantitative assessment of blast populations and supports monitoring of changes in CD34 expression during disease progression or therapeutic intervention. The ability to reliably detect and quantify CD34-positive cells is essential for studies focused on tumor heterogeneity and progenitor cell dynamics.

Clone ICO-115 is a mouse monoclonal antibody supported by multiple peer-reviewed publications, providing a well-established reagent for CD34 detection in flow cytometry. Its use in published studies supports confidence in its performance for identifying CD34-positive cells in both normal and malignant contexts. The antibody produces clear population separation, enabling accurate discrimination of blast cells and supporting downstream analytical workflows.

In multiparameter flow cytometry panels, CD34 is frequently combined with markers such as CD117, CD13, CD33, and HLA-DR to further define leukemia-associated immunophenotypes and characterize malignant cell populations. These marker combinations enable detailed profiling of disease-specific cellular subsets and support classification and stratification studies in hematologic research.

Careful gating strategies are required to distinguish malignant CD34-positive blast cells from normal progenitor populations, particularly in samples containing mixed cell types. Flow cytometry provides the resolution necessary to make these distinctions, enabling accurate interpretation of CD34 expression patterns in disease contexts.

Overall, CD34 Antibody for FACS is a critical reagent for leukemia research, enabling precise identification of CD34-positive blast populations and supporting detailed immunophenotypic analysis of hematologic malignancies and cancer stem cell compartments.

This antibody is part of our CD34 antibody collection, supporting research into stem cell biology, endothelial markers, and tumor angiogenesis.

## Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD34 Antibody for FACS / Leukemia Stem Cell Marker Antibody to be titered up or down for optimal performance.

## Immunogen

Blast cells from a chronic myeloid leukemia patient were used as the immunogen for this CD34 antibody.

## Storage

Store the CD34 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

## Alternate Names

CD34 leukemia marker antibody, CD34 blast cell marker antibody, CD34 hematologic malignancy antibody, CD34 stem cell leukemia antibody, CD34 FACS antibody clone ICO-115

References (2)


Copyright © NSJ Bioreagents. All rights reserved.